Trial reportAntimicrobial agents and chemotherapy2002
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.
Trial report in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.Antimicrobial agents and chemotherapy · 2005Trial
- Protocol to generate microglia-containing cerebral organoids to model HIV neuroinflammation.STAR protocols · 2026Article
- A nanopore-based HIV-1 reference epitranscriptome.Nucleic acids research · 2026Article
- Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.Retrovirology · 2017Article
- Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1.Cell cycle (Georgetown, Tex.) · 2017Article
- The dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C).Oncotarget · 2017Article
- Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.Current pharmaceutical design · 2016Review
- Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Clinical pharmacokinetics · 2015Article
- Overexpression of mitochondrial antioxidant manganese superoxide dismutase (MnSOD) provides protection against AZT- or 3TC-induced endothelial dysfunction.Antiviral research · 2014Article
- Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Clinical pharmacokinetics · 2014Review
- Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.Journal of pharmacokinetics and pharmacodynamics · 2014Article
- Antiretroviral bioanalysis methods of tissues and body biofluids.Bioanalysis · 2013Review
- CSF penetration by antiretroviral drugs.CNS drugs · 2013Review
- Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women.The open AIDS journal · 2012Article
- How much do antiretroviral drugs penetrate into the central nervous system?Journal of medicine and life · 2011Review
- Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.Topics in antiviral medicine · 2011Review
- Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.The Journal of antimicrobial chemotherapy · 2011Article
- Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice.Neurotoxicity research · 2011Article
- Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Clinical microbiology reviews · 2010Review
- Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India.The Indian journal of medical research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy. While studies suggest that saquinavir concentrations decrease over time, we show that concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid are stable during 2 years of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.